- Revenues +11.6%, Adjusted EBITDA +13.1% - Organic development compared to pro forma figures Q1 2024: revenues -6.5%, adjusted EBITDA -9.3% - Q1 significantly influenced by revenue shift in syringe business - Guidance 2025 confirmed: organic revenue growth of 3-5% and adjusted EBITDA...
Read More Details
Finally We wish PressBee provided you with enough information of ( Gerresheimer: Bormioli Pharma boosts revenues and earnings )
Also on site :